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Abstract
 
The T-box transcription factor T-bet is known to control lineage commitment and interferon-
 
 
 
production by T helper 1 (Th1) CD4 lymphocytes. We report here that T-bet is essential for
development of CD8 lymphocyte-dependent autoimmune diabetes (type 1 diabetes [T1D]) in
the rat insulin promoter–lymphocytic choriomeningitis virus (LCMV) transgenic model for
virally induced T1D. In the absence of T-bet, autoaggressive (anti-LCMV) CD8 lymphocytes
were reduced in number and produced less IFN-
 
 
 
, but increased IL-2 compared with controls.
Further analysis showed that T-bet intrinsically controls the generation, but not apoptosis,
maintenance, or secondary expansion of antiviral effector/memory CD8 lymphocytes. This
observation points toward a therapeutic opportunity for the treatment of T1D and other autoim-
mune disorders.
Key words: autoimmunity • T cell memory • cytokines • lymphocytic choriomeningitis virus • 
transcription factors
 
Introduction
 
Modulating the cytokine balance of autoreactive T lympho-
cytes can be of great value for preventing development of
autoimmune disorders. In type 1 diabetes (T1D), autoaggres-
sion is supported by IFN-
 
 
 
, IL-12, and cytotoxic activity,
whereas counter-regulation is achieved by Th2 cytokines
such as IL-4, IL-5, and possibly IL-10. Therefore, we
wished to explore the role of the recently discovered (1)
transcription factor T-bet in T1D because it was known
that T-bet controls lineage commitment and IFN-
 
 
 
 pro-
duction by CD4 T cells (1, 2). The significant Th2 shift in
T-bet–deficient mice can lead to an asthmalike syndrome
(3). This type of skewing of the cytokine equilibrium occurs
on a systemic level and also extends to the mucosal com-
partment (4, 5). Thus, T-bet appears to be a master controller
of the Th1 cytokine pathway and might constitute a mech-
anism for “cytokine memory” in T helper cells, as much as
GATA-3 controls Th2 lineage commitment (6). Interestingly,
although Th1 cell function is markedly impaired in the
absence of T-bet, IFN-
 
 
 
 production by CD8 T cells after
polyclonal stimulation is unaffected (2).
A suitable diabetes model to test the role of T-bet on
CD8 responses in vivo during T1D is the rat insulin pro-
moter (RIP)–lymphocytic choriomeningitis virus (LCMV)
mouse developed by Oldstone and Zinkernagel (7, 8).
These transgenic mice express viral antigens derived from
LCMV under control of the RIP in pancreatic 
 
 
 
 cells (9).
Viral infection with LCMV induces rapid CD8-dependent
diabetes in RIP-LCMV-glycoprotein (GP) transgenic lines.
Importantly, the infection is first cleared in these mice before
the autoimmune process fully develops. Therefore, islet
autoimmunity is governed by different immunological rules
compared with clearance of the systemic LCMV infection,
and treatments that abrogate the diabetogenic process need
not necessarily impair viral clearance (10, 11). Lymphocytes
infiltrating the islets are of the experienced (effector/memory)
phenotype, which is characterized functionally by con-
comitant production of TNF-
 
 
 
 and IFN-
 
 
 
, but not IFN-
 
 
 
alone (12, 13). Islet destruction depends on production of
inflammatory cytokines such as IL-12 and IFN-
 
 
 
 in addition
to cytolytic effector function by autoaggressive (anti-
LCMV) CD8 lymphocytes (10, 14).
 
Address correspondence to Matthias G. von Herrath, Div. of Develop-
mental Immunology, La Jolla Institute for Allergy and Immunology,
10355 Science Center Dr., San Diego, CA 92121. Phone: (858) 558-
3571; Fax: (858) 558-3579; email: matthias@liai.org
 
Abbreviations used in this paper:
 
 BGV, blood glucose value; GP, glycoprotein;
LCMV, lymphocytic choriomeningitis virus; RIP, rat insulin promoter;
T1D, type 1 diabetes. 
T-bet Is Essential for T1D and CD8 Memory
 
1154
Based on these arguments, the RIP-LCMV model ap-
peared to be an ideal tool for evaluating the role of T-bet in
CD8 responses in autoimmunity. The suitability of RIP-
LCMV mice as a valid diabetes model for our analysis is fur-
ther supported by the fact that more recently a strong role
for CD8 cells as the final effectors in 
 
 
 
 cell destruction has
been found (14–17). In addition, antigenic spreading occurs
in our RIP-LCMV-GP lines as evidenced by autoantibod-
ies to insB and GAD preceding the onset of T1D (18). Fi-
nally, diabetes in RIP-GP mice occurs in a CD4-indepen-
dent fashion (9, 19), and the effect of T-bet on CD8
responses can be segregated from its known effect on CD4
T cells. In the studies reported here, we found a dramatic
reduction of disease. This is associated with a decrease of is-
let infiltration and significant reduction of LCMV-specific
(“anti-self”) memory CD8 responses. Blocking the activity
of T-bet might be of unique therapeutic value in preventing
T cell–mediated autoimmune disorders.
 
Materials and Methods
 
Mice.
 
Mice deficient in T-bet (T-bet
 
   
 
) were generated on
a C57BL/6 
 
 
 
 129 background as described previously (2). T-
bet
 
   
 
 mice were backcrossed three times to C57BL/6 before
being crossed to RIP-GP (7, 9) to obtain T-bet
 
   
 
 
 
 
 
 RIP-GP mice.
These mice were intercrossed to obtain T-bet
 
   
 
, T-bet
 
   
 
, and
T-bet
 
   
 
 
 
 
 
 RIP-GP. In some experiments, nontransgenic
T-bet
 
   
 
 or 
 
   
 
 and 
 
   
 
 littermate control mice were used. Mice
were housed under specific pathogen-free conditions at La Jolla
Institute for Allergy and Immunology.
 
Viruses.
 
LCMV Armstrong clone 53b (20) plaque-purified
three times on Vero cells and stocks prepared by a single passage
on BHK-21 cells were used throughout experiments. 6–10-wk-
old mice were infected with a single dose of 10
 
5
 
 PFU i.p.
 
Blood Glucose Values.
 
Blood glucose was monitored with
OneTouch Ultra at weekly intervals. Diabetes was defined as
blood glucose values (BGVs) over 300 mg/dl (21).
 
Peptides.
 
Peptides used for viral studies were the dominant
D
 
b
 
-restricted LCMV epitopes GP
 
33–41
 
 and NP
 
396–404
 
 (The Scripps
Research Institute Peptide Core Facility; reference 22) as well as
I-A
 
b
 
–restricted epitope GP
 
61–80
 
 (Chiron Corp.; reference 23).
 
Immunohistochemistry.
 
Tissues were immersed in Tissue-Tek
OCT (Bayer) and quick frozen on dry ice. Using cryomicrotome
and sialin-coated Superfrost Plus slides (Fisher Scientific), 6–10-
 
 
 
m
tissue sections were cut. Sections were fixed with 90% ethanol at
 
 
 
20
 
 
 
C, and, after washing in PBS, an avidin/biotin-blocking
step was included (Vector Laboratories). Primary and biotinylated
secondary antibodies (Vector Laboratories) were reacted with the
sections for 60 min each, and color reaction was obtained by
sequential incubation with avidin–peroxidase conjugate (Vector
Laboratories) and diaminobenzidine–hydrogen peroxide. Primary
antibodies used were rat anti–mouse CD8a (Ly2) and rat anti–
mouse CD4 (L3T4; BD Biosciences).
 
Flow Cytometry.
 
For intracellular stains, single cell suspensions
were restimulated for 5 h with 1 
 
 
 
g/ml MHC class I–restricted
viral peptides, 2 
 
 
 
g/ml MHC class II–restricted viral peptides, or
2 
 
 
 
g/ml anti-CD3 and anti-CD28 in the presence of brefeldin A
(Sigma-Aldrich). Cells were stained for surface expression of
CD4 and CD8, fixed, permeabilized, and stained for intracellular
IFN-
 
 
 
, TNF-
 
 
 
, or IL-2. CCR7 staining was performed by incu-
bation with ELC-Ig followed by goat anti–human Fc-FITC (24).
D
 
b
 
GP
 
33
 
 and D
 
b
 
NP
 
396
 
 MHC class I tetramers were produced as
described previously (25). Samples were acquired using a FACS-
Calibur™ (Becton Dickinson).
 
ELISPOT Assay.
 
Membrane-bottom 96-well plates were
coated overnight with IL-4 or IFN-
 
 
 
 capture antibodies. Spleno-
cytes were plated at various dilutions and cultured at 37
 
 
 
C, 5%
CO
 
2
 
 with GP
 
61
 
 MHC II–restricted viral peptide. After 24 h (IFN-
 
 
 
)
or 48 h (IL-4), the plates were washed, the cells were removed,
and an IFN-
 
 
 
 or IL-4 detection antibody was added at 4
 
 
 
C over-
night. A streptavidin/angiotensin-converting enzyme color reac-
tion was used to identify cell cytokine secretion patterns, and the
spots were counted with the aid of a dissection microscope.
 
In Vitro Restimulations.
 
For LCMV-specific responses, mem-
ory splenocytes were cultured for 6 d on LCMV-infected irradi-
ated peritoneal exudate cells. After culture, viable cells were col-
lected, and cells were incubated for 5 h with peptide in the
presence of brefeldin A before staining for intracellular IFN-
 
 
 
.
The fold increase of specific CD8
 
 
 
 cells was calculated by divid-
ing the absolute number of IFN-
 
 
 
 
 
 CD8
 
 
 
 cells after in vitro cul-
ture by the absolute number of IFN-
 
 
 
 
 
 CD8
 
 
 
 cells at the start of
the culture.
 
ELISA.
 
Quantitation of cytokines in cell culture superna-
tants after in vitro stimulation was performed in a sandwich
ELISA. For IL-4, IL-10, and IFN-
 
 
 
 assays, 96-well plates were
precoated overnight at 4
 
 
 
C with purified capture antibodies (BD
Biosciences). After washing and blocking, serial dilution of super-
natants and recombinant cytokine standards (BD Biosciences)
were incubated overnight at 4
 
 
 
C. Plates were further incubated
with matched biotinylated detection antibodies and a streptavi-
din–peroxidase conjugate. For color reaction, H
 
2
 
O
 
2
 
-activated
2,2’-Azino-di-[3-ethylbenzthiazolin-6-sulfonic acid] (ABTS; Sigma-
Aldrich) solution was added. Plates were read at 405 nm. For
TGF
 
 
 
 quantitation, the TGF
 
 
 
1 Emax ImmunoAssay kit (Promega)
was used.
 
Adoptive Transfers.
 
CD8
 
 
 
 T cells were purified from GP
 
33
 
TCR-tg (26) or T-bet
 
   
 
, 
 
   
 
, or 
 
   
 
 donors by negative selec-
tion (Dynal). 10
 
4 
 
GP
 
33
 
 TCR-Tg cells were transferred i.v. into
T-bet
 
   
 
, 
 
   
 
, or 
 
   
 
 recipients.
 
Generation of Mixed Bone Marrow Chimeras.
 
Bone marrow
was isolated from tibias and femurs of donor T-bet
 
 
 
/
 
 
 
, T-bet
 
   
 
,
or C57Bl/6 Thy1.1 congenic mice. Bone marrow was depleted
of CD4 and CD8 T cells, and a 1:1 mixture containing a total of
10
 
7
 
 cells was injected i.v. into lethally irradiated (1,100 rad)
T-bet
 
   
 
 or T-bet
 
   
 
 recipients. Mice were allowed to reconsti-
tute over a period of 6 wk, which was confirmed by FACS
 
®
 
 analy-
sis of peripheral blood lymphocytes before infection with LCMV.
 
Results
 
Drastically Reduced T1D in T-bet–deficient Mice.
 
To ex-
amine a role for T-bet in autoimmune diabetes (T1D),
T-bet
 
   
 
 mice were crossed to RIP-GP transgenic mice.
T-bet
 
   
 
, T-bet
 
   
 
 or T-bet
 
   
 
 
 
 
 
 RIP-GP littermates
were infected with 10
 
5
 
 PFU LCMV Armstrong to induce
diabetes. BGVs were measured weekly, and by 2 wk after
infection, 80–100% of T-bet
 
   
 
 or T-bet
 
   
 
 
 
 
 
 RIP-GP
mice were diabetic (Fig. 1 A), with average BGVs of 
 
 
 
500
mg/dl (Fig. 1 B). In these experiments, a small percentage
of the diabetic mice reverted to normal BGVs at 
 
 
 
3 wk af-
ter infection. This has been described previously in mice of
a mixed 129 
 
 
 
 B6 background (27). However, by 35 d af- 
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ter infection, 75–80% of T-bet
 
   
 
 and T-bet
 
   
 
 
 
 
 
 RIP-GP
mice remained diabetic. In contrast, most of the T-bet
 
   
 
 
 
 
 
RIP-GP had normal BGVs on day 14 (Fig. 1 B), averaging
 
 
 
200 mg/dl. In addition, diabetes incidence in T-bet
 
   
 
 
 
 
 
RIP-GP remained dramatically reduced with only 10% dia-
betic (Fig. 1 A) 35 d after infection. Thus, elimination of
T-bet results in a highly significant reduction (P 
 
 
 
 0.0001
by Student’s 
 
t
 
 test) of BGVs and autoimmune diabetes.
 
Reduced Islet Infiltration in T-bet–deficient Mice. 
 
Pancre-
ata from T-bet   RIP-GP mice were examined by immu-
nohistochemistry for the presence of CD4 and CD8 T
cells. Islets from diabetic T-bet      RIP-GP mice were
heavily infiltrated with both CD4 and CD8 T cells. In con-
trast, islets from T-bet      RIP-GP had less severe infil-
tration, with CD4 and CD8 T cell present mostly around
the periphery of the islets (Fig. 1 C).
Defect in Effector/Memory CD8s in T-bet–deficient Mice.
The CD8 immune response to LCMV is characterized by
an initial primary expansion of LCMV-specific, IFN-  sin-
gle positive T cells, peaking  7–8 d after infection. This is
followed by a contraction phase leaving resting LCMV
memory CTLs that can turn into IFN- /TNF-  double
positive effector/memory CD8 T cells upon antigenic re-
stimulation. Subsequently, memory CD8 T cells are main-
tained at a similar frequency for life. The frequency of
LCMV-specific CD8 lymphocytes was evaluated over
time. Primary CD8 T cell responses examined on day 8 af-
ter LCMV infection were not impaired in T-bet–deficient
mice as evidenced by unimpaired IFN-  production (Fig. 2
A) and cytotoxicity toward LCMV-infected targets (not
depicted). Accordingly, viral clearance was not affected
(unpublished data). This was not unexpected because this
particular primary antiviral response occurs independently
of many immunological parameters, including B7, IFN- ,
CD4 help, CD28, and CD40L (28–35). In addition, previ-
ous studies have demonstrated that the primary immune re-
sponse on day 8 does not correlate with disease, whereas
effector/memory cells do (36, 37).
In contrast, and consistent with the reduction of autoim-
mune diabetes, antigen-specific effector/memory CD8 T
cells were dramatically reduced by day 14 after LCMV in-
fection, with 2% IFN-  positive cells in T-bet    mice af-
ter culture with GP33, compared with 10% in T-bet   
mice (Fig. 2 A). The reduction seen at this time point is
likely to be highly relevant in terms of diabetes induction
because it corresponds exactly to the peak of clinical disease
in control mice. This lower number of LCMV-specific
CD8 T cells after day 14 is maintained in T-bet    mice
over time (Fig. 2 A). In agreement with the reduced num-
ber of IFN-  positive effector/memory CD8 lymphocytes
after 5 h stimulation with peptide is the reduced amount of
IFN-  in tissue culture supernatants assessed by ELISA after
a 3-d stimulation period (Fig. 2 A). Despite the signifi-
cantly reduced IFN-  production, there was no compensa-
tory increase in the production of Tc2 cytokines, such as
IL-4, IL-10, and TGF- . LCMV-specific production of
IL-4, IL-10, or TGF-  by CD8 T cells could not be de-
tected by ELISA or ELISPOT in T-bet    or T-bet   
mice (see Fig. 6 D and not depicted). Thus, antigen-spe-
cific CD8 effector/memory responses in T-bet–deficient
mice are markedly impaired.
Phenotypically, effector/memory CD8 cells are predom-
inantly present in islets of diabetic RIP-GP mice and se-
crete TNF-  in addition to IFN-  (12). To assess the ac-
tivity of autoaggressive (LCMV specific) CD8 lymphocytes
in proximity to the target organ, antigen-specific produc-
tion of IFN-  and TNF-  by CD8 T cells was examined
in T-bet   RIP-GP mice 1 mo after infection. Cells were
Figure 1. T-bet    mice are resistant to diabetes. T-bet   , T-bet   ,
or T-bet      RIP-GP mice were infected i.p. with 105 PFU LCMV
Armstrong. Incidence of diabetes (A) or BGVs of individual mice on day 14
after infection (B) are shown. Mice were considered diabetic when BGVs
were  300 mg/dl. Tissue sections were cut and analyzed for islet infiltration
(C) using monoclonal antibodies specific for CD8 and CD4. Sections
were counterstained with hematoxylin. Staining shown is from the same
islets present on consecutive sections, and represents the average degree of
infiltration present. Photographs were shot at a magnification of 20, and
some photos were additionally enlarged using photo-processing software.T-bet Is Essential for T1D and CD8 Memory 1156
pooled from the spleen or pancreatic draining LNs of
T-bet    and T-bet      RIP GP mice and were stimu-
lated in vitro with the MHC class I LCMV peptides GP33
or NP396, or with anti-CD3 and anti-CD28. Intracellular
cytokine staining was performed to determine antigen-spe-
cific IFN-  and TNF-  production. Compared with dia-
betic T-bet    mice, T-bet    mice exhibited an  50%
decrease in double cytokine–producing (TNF-  and
IFN- ) effector/memory CD8 T cells specific for GP33
and NP396 in the spleen (Fig. 2 B) and pancreatic lymph
node (Fig. 2 C) at 1 mo after LCMV infection. IFN-  and
TNF-  production by CD8 T cells was also reduced in
T-bet    mice after polyclonal stimulation with anti-CD3
and -CD28 1 mo after LCMV infection (Fig. 2, B and C).
Thus, effector functions of LCMV-specific autoaggressive
lymphocytes were significantly reduced in the pancreatic
draining lymph node of T-bet–deficient RIP-GP mice.
Numeric Reduction of Effector/Memory Cells in T-bet   
Mice.  The aforementioned results demonstrated a re-
duced frequency of LCMV-specific CD8 T cells in T-bet   
mice. To determine if this was due to an overall nu-
meric reduction in antigen-specific T cells, the number of
LCMV-specific T cells per spleen was determined after
peptide restimulation and IFN-  staining. There were
fewer IFN-   LCMV-specific CD8 T cells in spleens of
T-bet    mice compared with T-bet    or     controls 1
mo after infection (Fig. 3 A). In addition, splenocytes were
stained with H-2Db tetramers loaded with GP33 or NP396
peptides to ensure that the reduced frequency of IFN-  
cells as measured by intracellular cytokine staining reflected
a reduction in the actual number of LCMV-specific CD8
memory T cells. As shown in Fig. 3 B, there was also a re-
duction of GP33 or NP396-specific CD8 T cells in T-bet   
mice compared with controls after tetramer staining. Thus,
deficiency of T-bet results in reduced numbers of CD8
memory lymphocytes in vivo. Splenocytes were also
stained for the expression of CCR7 to enumerate the fre-
quency of effector/memory versus central memory T cells.
On day 14 after LCMV infection, there was a significantly
lower percentage of LCMV-specific effector/memory
CD8 T cells (CD8 , NP396
 , CCR7neg) in T-bet    mice
(Fig. 3 C). CCR7 staining was also performed on day 28.
T-bet    mice still had a lower percentage of effector/
memory T cells, but the difference from controls was not
statistically significant, and much less dramatic than ob-
served on day 14 (Fig. 3 C).
Effector Functions Not Impaired on a Per Cell Basis.  The
ability of T-bet    memory T cells to expand in response
to reexposure to LCMV in vitro was examined. As shown
in Fig. 4 A, CFSE-labeled memory splenocytes from
T-bet    mice do proliferate, although the overall percent-
age of GP33-specific cells is still reduced compared with
controls after 6 d of culture. Because the LCMV-infected
T-bet    mice typically have approximately threefold
fewer LCMV-specific T cells ex vivo, the fold increase in
LCMV-specific T cells was determined by dividing the ab-
solute number of GP33-specific T cells present after culture
by the number present ex vivo. Using this calculation, the
Figure 2. Drastic reduction of autoaggressive memory effector
CD8 lymphocytes in the absence of T-bet. T-bet   , T-bet   ,
and T-bet    mice were infected with 105 PFU LCMV and killed
at the indicated days after infection. Spleen cells were cultured
with GP33 peptide for 5 h for intracellular IFN-  staining or for
72 h for ELISA (insets). Data for the intracellular cytokine staining
are graphed as the percent IFN-   of CD8 gated populations and
are an average of at least three mice per group per time point (A).
Diabetic T-bet    or protected T-bet      RIP-GP mice were
killed 4 wk after infection, and spleen (B) or pancreatic LNs (C)
were pooled. Single cell suspensions were incubated with GP33 or
NP396 MHC-I peptides, or anti-CD3/CD28 and stained for intra-
cellular IFN-  and TNF- . Plots are gated on CD8  T cells with
percentages shown in relative quadrants.Juedes et al. 1157
proliferation of T-bet    GP33-specific CD8 T cells after
6 d in culture is as good or better than T-bet    T cells
(Fig. 4 B). Furthermore, the mean fluorescent intensity of
IFN-  production was equivalent comparing memory
CTL from T-bet    and     mice (Fig. 4 C). It is interest-
ing that, despite a numeric reduction in CD8 memory T
cells in vivo, these cells were still competent to expand in
vitro in the presence of antigen (virus or peptide). Thus, al-
though the numbers of effector/memory cells are reduced
in T-bet–deficient mice, their ability to respond to antigen
with proliferation, cytolytic activity (unpublished data), and
IFN-  production is completely intact when assessed on a
per cell basis. Therefore, we conclude that generation of
memory CTL in T-bet    mice is defective, but that the
remaining effector/memory cells found in T-bet    mice
are functionally competent.
Defective CD8 Response Does Not Rely on IL-2.  It has
been shown previously that one of the functions of T-bet is
to repress the IL-2 promoter (1). Accordingly, we exam-
ined IL-2 production by CD8 T cells after infection with
LCMV. On day 8 after infection, LCMV-specific CD8 T
cells from T-bet    and T-bet    mice produced more IL-2
compared with T-bet   . As shown in Fig. 5 A, T-bet   
mice have a higher frequency of IFN- , IL-2  GP33-spe-
cific CD8 T cells compared with T-bet    mice ( 6 vs.
1%, respectively). T-bet    mice showed an intermediate
phenotype with  3% of CD8 T cells producing IL-2 in re-
sponse to GP33. IL-2 production was also examined at the
memory stage. Although the absolute number of LCMV-
specific CD8 T cells is reduced in T-bet    mice, the ratio
of IL-2  to IL-2  LCMV-specific CD8 T cells is still much
higher in T-bet    compared with T-bet    (Fig. 5 A).
The higher levels of autologous IL-2 production by CD8 T
cells in T-bet    mice was unable to rescue the memory
defect in vivo, despite the fact that IL-2 is a key helper fac-
tor for programming CD8 memory (38).
Interestingly, a recent paper demonstrated that in vivo
administration of IL-2 during the expansion phase (days
0–8) resulted in fewer antigen-specific T cells and more
apoptosis (39). Thus, it was possible that the enhanced IL-2
production by T-bet    CD8 T cells during the acute phase
of infection might actually be partially responsible for the
Figure 3. Numeric reduction of IFN- –producing CD8 T cells in
T-bet    mice. T-bet   , T-bet   , and T-bet    mice were infected
with 105 PFU LCMV. Spleen cells isolated  30 d after infection were
cultured with the indicated LCMV MHC-I peptides before staining for
intracellular IFN- . The total number of antigen-specific cells per spleen
was calculated by multiplying the percent CD8/IFN-  double positive
cells by the total number of cells isolated from the spleen of each mouse.
Statistically significant differences (P   0.005 by Student’s t test) were
found between     and     (A). Cells isolated on day 30 after LCMV
were stained with CD8 and Db GP33 or NP396 tetramers. Representative
data are from one out of four experiments (B). Cells isolated on day 14
(left) or 28 (right) were stained with Db NP396 tetramers and ELC-Ig to
detect CCR7. The data are an average of four to five mice per group and
are graphed as the percentage of CCR7 negative cells within NP396
 
gated populations (C).
Figure 4. Normal proliferation and secondary expansion of LCMV-
specific effector/memory CD8 cells in T-bet    mice. Spleens cells isolated
from mice infected with LCMV  30 d previously were labeled with
CFSE and were cultured for 6 d on LCMV-infected irradiated peritoneal
exudate cells. After a 5-h restimulation with GP33 and brefeldin A, staining
for intracellular IFN-  was performed (A). The fold increase of LCMV-
specific CD8 T cells was calculated by dividing the number of IFN-  
GP33-specific T cells after 6 d of culture by the number present directly ex
vivo (B). Median fluorescence intensity for intracellular IFN-  was deter-
mined after a 5-h culture of spleen cells with GP33 (C).T-bet Is Essential for T1D and CD8 Memory 1158
defect in effector/memory T cells. To examine this, annexin
V staining was performed on LCMV tetramer positive cells
at days 9, 10, and 12 after infection with LCMV. Com-
pared with T-bet    or     controls, T-bet    mice did not
have significantly enhanced levels of annexin V  antigen-
specific cells (Fig. 5 B). To ensure that possible differences
in apoptosis were not masked by the rapid clearance of ap-
optotic cells in vivo, these experiments were repeated in
vitro. Splenocytes were harvested on day 8 after LCMV in-
fection and were cultured for 1, 2, or 3 d in medium before
staining for annexin V on tetramer positive cells. These
studies also revealed that T-bet    mice did not have ele-
vated levels of apoptosis compared with controls (Fig. 5 C).
Thus, increased contraction of the primary immune re-
sponse by apoptosis is not the cause for reduced levels of ef-
fector/memory CD8 CTL in T-bet    mice.
Defect in the Effector/Memory Response in T-bet–deficient
Mice Is CD8 Intrinsic.  Autoimmune diabetes occurs inde-
pendently of CD4 help in RIP-GP mice (9, 19). Thus, the
resistance to diabetes of T-bet    GP  mice cannot directly
Figure 5. The impaired CD8 memory T cells in T-bet    mice are
neither caused nor rescued by enhanced autologous IL-2 production.
Spleens were harvested at day 8 (top) or day 30 (bottom) after infection,
and cells were cultured with the MHC-I LCMV peptides. Cells were
stained for intracellular IL-2 and IFN-  and plots were gated on CD8 T
cells. Data are representative of six to eight mice examined per group,
with P   0.005 when comparing IL-2 production by T-bet    and T-bet   
(A). T-bet   ,    , or     mice were infected with LCMV, and peripheral
blood was analyzed at the indicated days after infection (B). Alternatively,
spleen cells from mice infected with LCMV 8 d previously were cultured
in vitro for 1–3 d in medium alone (C). Cells were stained with CD8 and
Db NP396 tetramers before staining for annexin V. Data are graphed as the
percent annexin V  of tetramer gated populations and are an average of
three to four mice per group.
Figure 6. Reduced LCMV-specific Th1 without increased Th2 cells in
T-bet    mice. Spleen cells from mice infected with LCMV 30 d previously
were cultured with LCMV MHC-II peptide GP61, and intracellular IFN- 
production by CD4 T cells was determined. Data are an average of three
mice per group (A). ELISA for IL-10 (B) or ELISPOT assays for IFN- 
and IL-4 (C) were performed using day 8 spleen cells cultured with GP61
MHC class-II peptide. For IFN-  responses by CD4 cells, statistically
significant results (P   0.005 by Student’s t test) were obtained when
comparing IFN-  production by T-bet / , T-bet / , and T-bet   . For
TGF-  ELISA, spleen cells from mice infected with LCMV 30 d previ-
ously were cultured with medium alone, MHC-I peptide GP33, or MHC-II
peptide GP61 as indicated (D).Juedes et al. 1159
be explained by the profound CD4 helper Th1 defect that
has been demonstrated in previous studies (2). However, it
was still possible that the reduced number of CD4 Th1
lymphocytes in T-bet    mice affected generation of CD8
memory. Indeed, memory CD8 responses after LCMV in-
fection depend on CD4 helper activity for maintenance
and effector programming (35, 38). We sought to resolve
this issue.
As expected, LCMV-specific, IFN- –secreting CD4 Th1
cells were decreased in T-bet    mice. At both the memory
stage (Fig. 6 A), and at the acute phase of infection on day 8
(Fig. 6 C), IFN-  production by CD4 T cells from T-bet   
mice was greatly reduced. LCMV-specific CD4 T cells
from heterozygous T-bet    mice were also substantially re-
duced in number (Fig. 6, A and C), consistent with the
gene-dosage effect observed previously (1, 2). Because both
T-bet heterozygous ( / ) and T-bet    mice exhibit a
similar defect in LCMV-specific CD4 T cells (Fig. 6), but
the former maintains completely normal LCMV-specific
memory CD8 T cell responses (Fig. 2), it is unlikely that a
T-bet–dependent CD4 defect alone can account for the de-
fective  -LCMV CD8 memory response observed. Indeed,
attempts to correct the CD8 memory generative defect in
T-bet    mice by adoptive transfer of 10–30   106 naive
CD4 T-bet    lymphocytes before LCMV infection failed
to correct the memory defect (Fig. 7 A).
It was possible that in the absence of T-bet, CD4 T cells
would default to the Th2 pathway in context of the viral
(LCMV) infection as described previously in unprimed
mice (3). Therefore, ELISPOT assays for IL-4 or ELISAs
for IL-10 and TGF-  were performed using splenocytes
stimulated with GP61. Although the CD4 T cells from
T-bet    and T-bet /  mice produced reduced levels of
IFN-  compared with controls, there was no significant in-
crease in antigen-specific IL-10, IL-4, or TGF-  produc-
tion (Fig. 6, B–D). Thus, it is very unlikely that Th2 devia-
tion would affect CD8 memory responses in T-bet    via
bystander suppression, as described previously in other ex-
perimental settings for antigen-induced regulatory cells (11).
To further examine the notion that T-bet    CD8 T
cells have an intrinsic defect, a series of adoptive transfer ex-
periments was performed. GP33-TCR-tg C57Bl/6 (WT) T
cells were transferred into T-bet / ,    , or     recipients
before infection with LCMV. Although the adoptive trans-
fer of TCR transgenic T cells reduced the overall frequency
of the endogenous CD8 T cell response, T-bet    mice still
had fewer endogenous NP396-specific T cells compared
with T-bet    on day 14 (Fig. 7 B). In contrast, the fre-
quency of GP33-specific T cells was normal in T-bet   
mice (Fig. 7 B). Thus, WT GP33-TCR-tg CD8 T cells
were not impaired in an otherwise T-bet–deficient environ-
ment. In addition, mixed bone marrow chimeras were cre-
ated to further demonstrate an intrinsic defect in T-bet   
CD8 T cells. Bone marrow was isolated from donor
T-bet   , T-bet   , or C57Bl/6 (WT) Thy1.1 congenic
mice. A mixture of T-bet    and WT Thy1.1 bone marrow
was injected into lethally irradiated recipients. As a control,
T-bet    and WT Thy1.1 mixed bone marrow chimeras
were also generated. Mice were rested for 6 wk, and the
percentage of Thy1.2  (T-bet    or T-bet   ) CD8 T cells
was determined in peripheral blood. Both T-bet    and
T-bet    chimeras expressed Thy1.2 on 50–60% of peripheral
blood CD8 T cells, indicating that the chimerism had been
achieved (Fig. 7 C). Mice were subsequently infected with
LCMV, and the frequency of Thy1.1 (WT) and Thy1.2
(T-bet    or    ) LCMV-specific CD8 T cells was determined
on day 14. The generation of LCMV-specific T-bet   
CD8 T cells was dramatically impaired in WT/KO mixed
bone marrow chimeras. Thy1.2  (T-bet   ) CD8 T cells
accounted for  60% of total CD8 T cells before infection,
Figure 7. The effector/memory defect in T-bet    mice is CD8 intrinsic.
T-bet    CD4 T cells were purified by negative selection, and 1–3   107
cells were transferred into T-bet    recipients. Mice were infected with
LCMV and analyzed 30 d later (A). Naive GP33-TCR-tg CD8 T cells
were transferred into T-bet / , T-bet   , or T-bet    recipients 1 d before
infection with LCMV. The percentage of GP33 or NP396-specific CD8 T
cells as determined by intracellular IFN-  staining is shown 14 d after
infection (B). Mixed bone marrow chimeras were created using a 1:1
mixture of C57Bl/6 Thy1.1 congenic bone marrow and Thy1.2 T-bet   
(C, left) or Thy1.2 T-bet    (C, right) bone marrow. After 6 wk to allow
reconstitution, the frequency of Thy1.1 (unshaded bars) or Thy1.2
(shaded bars) CD8 T cells in the blood was determined (day 0). Mice
were infected with LCMV and splenocytes were isolated 14 d later. The
percentage of GP33-specific T cells that expressed Thy1.1 or Thy1.2 was
determined after intracellular cytokine staining. Data are an average of
three mice per group with indicated standard deviations.T-bet Is Essential for T1D and CD8 Memory 1160
whereas they represented only  16% of GP33-specific T
cells on day 14 after infection (Fig. 7 C). In contrast, control
WT/T-bet    chimeras had a similar fraction of Thy1.2 
LCMV-specific CD8 T cells compared with preinfection.
These results demonstrate that the generation of T-bet   
memory CD8 T cells is impaired in the very same immuno-
logical environment that allows the successful generation of
WT CD8 memory T cells.
Discussion
Here, we have demonstrated a critical role for the tran-
scription factor T-bet in the autoaggressive behavior of
CD8 lymphocytes. It is striking that the absence of T-bet so
profoundly affects the development of insulitis and diabetes
in a solely CD8-mediated model, as is the case in the RIP-
GP transgenic mouse (9). Our data appear to conflict with
earlier studies in T-bet    mice that failed to demonstrate an
IFN-  production defect in polyclonally activated primary
CD8 cells (2). However, we have recently obtained evi-
dence for an essential role for T-bet in antigen-driven as op-
posed to polyclonal, antigen-nonspecific generation and ef-
fector function of CD8 cells. In these studies, a profound
defect in CD8 function in the absence of T-bet was re-
vealed in an antigen-specific, TCR-transgenic setting (40).
The findings reported here extend these observations, and
demonstrate an intrinsic defect in the generation of effector/
memory CD8 T cells after viral infection in vivo.
Our data provide novel mechanistic insight as to how
T-bet functions in CD8 cells and demonstrate an intrinsic
defect in generation of effector/memory CTLs in the ab-
sence of this factor. Primary antiviral CD8 responses de-
velop equally in T-bet–competent or –deficient mice. This
is conceivable if one considers that primary immune re-
sponses to LCMV may follow different rules compared
with effector/memory and indeed, have been shown to be
independent of many immunological parameters including
B7, CD4 T cells, CD28, and CD40. However, in the ab-
sence of T-bet, lower numbers of effector/memory CD8
lymphocytes resulting in overall reduced IFN-  and TNF- 
production are found after LCMV infection. Their lack is
also evident in the pancreatic draining lymph node and tar-
get organ that harbors autoaggressive effector CD8 lym-
phocytes in RIP-LCMV mice.
The difference between T-bet    and T-bet    mice is
most dramatic on day 14, which corresponds to the peak of
clinical disease in the RIP-GP model. Studies performed
on day 14 revealed the largest difference in terms of the
number of IFN- –producing LCMV-specific T cells, as
well as a reduced percentage of CCR7neg effector/mem-
ory cells. It is likely that effector/memory cells, as opposed
to central memory, are the most important type of cell for
mediating immune pathology during T1D, due to their
ability to home to peripheral tissues (41).
What is the cause for defective antiviral CD8 memory in
T-bet–deficient mice? Although antigen-specific studies
performed with transgenic T cells demonstrated a Tc2 shift
in terms of IL-4 and IL-10 production (40), we did not ob-
serve any significant Tc2 (CD8) or Th2 (CD4) deviation in
the LCMV viral system. This discrepancy might be due to
the intrinsic Th1 skewing properties of virus infection as
compared with peptide stimulation alone. The absence of
Tc2/Th2 cytokines in the LCMV system makes the de-
crease in autoaggressive LCMV-specific CD8 response un-
likely to be due to counter-regulation, as has been de-
scribed previously in the RIP-LCMV system (11).
Because our studies demonstrate that reduced CD4 helped
and/or increased IL-2 were likely not the reasons for de-
creased CD8 memory, we assessed a role for another cyto-
kine important in CTL generation, IL-12. However, sys-
temic administration of IL-12 to T-bet knockout mice did
not resuscitate CD8 memory (unpublished data). Along
these lines, levels of IL-15, another cytokine critical in the
generation and maintenance of CD8 memory cells, was
normal in the bone marrow of T-bet    mice (unpub-
lished data).
Lastly, some consideration should be given to the role of
IFN-  in our system. IFN-  is an important factor in   cell
destruction and viral clearance (14, 37, 42). Thus, the re-
duction of T1D in T-bet    mice agrees well with reduced
levels of CD8 lymphocytes resulting in an overall decrease
in IFN-  and lytic activity. Furthermore, IFN- –deficient
mice exhibit intact primary CTL responses to LCMV,
whereas memory CTLs were reduced (37). If one considers
that the memory response is programmed in the LCMV
system during the primary antiviral response phase (38),
possible reduction of IFN-  levels at the time of the pri-
mary antiviral response might have resulted in an altered
program in memory CTL. Indeed, major amounts of
IFN-  by CD8 CTLs are generated early (days 6–9) after
LCMV infection. IFN-  can also be produced by other cell
types, such as dendritic cells and macrophages. A recent pa-
per demonstrated that IFN-  production by myeloid den-
dritic cells after culture with IL-12/IL-18 is reduced in the
absence of T-bet (43); this resulted in a modest reduction
in IFN-  production, but no proliferative defect by T cells
after in vivo priming with antigen-pulsed DCs (43). How-
ever, we have not detected any difference in the ability of
LCMV-infected T-bet    or T-bet    APCs to stimulate
LCMV-specific CD8 memory or naive T cells in vitro (un-
published data) or in vivo (Fig. 7 B). In addition, because
IFN-  levels made by primary LCMV CTLs in T-bet   
mice match those of T-bet    or     littermates (Fig. 2),
we argue that lack of IFN-  at the acute phase of infection
is not responsible for the observed defect in memory CTLs.
All of these data make it likely that the defect is intrinsic to
the CD8 cell rather than attributable to the cytokine
microenvironment. Most convincingly, our studies using
bone marrow chimeras demonstrate that the generation of
T-bet    memory CD8 T cells is impaired in the very same
immunological environment that allows the successful gen-
eration of WT CD8 memory T cells.
In conclusion, our observations indicate that small mole-
cule inhibitors of crucial transcription factors such as T-betJuedes et al. 1161
might offer a unique therapeutic opportunity for prevent-
ing autoimmunity. T1D likely depends on both autoag-
gressive CD4 as well as CD8 lymphocytes. Indeed, a po-
tent role for CD8 effector cells has been found more
recently in many T1D models (15–17). Therefore, the in-
trinsic CD8 defect specific for effector/memory cells but
not primary CD8 lymphocytes reported here in the ab-
sence of T-bet strengthens the rationale for targeting T1D.
It will need to be determined whether control of chronic
infections, or long-term immunity after vaccination is suffi-
cient in the absence of T-bet, although our results here
demonstrate that lack of T-bet does not render mice sus-
ceptible to an acute viral infection.
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